Mario Luca Morieri
Overview
Explore the profile of Mario Luca Morieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang M, Morieri M, Kalim S, Doria A
J Am Soc Nephrol
. 2025 Jan;
PMID: 39774583
No abstract available.
2.
Fadini G, Longato E, Morieri M, Bonora E, Consoli A, Fattor B, et al.
Diabetologia
. 2024 Aug;
67(11):2585-2597.
PMID: 39177691
Aims/hypothesis: We compared the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on renal outcomes in individuals with type 2 diabetes, focusing on the...
3.
Marassi M, Morieri M, Sanga V, Ceolotto G, Avogaro A, Fadini G
Curr Diab Rep
. 2024 Jul;
24(9):197-206.
PMID: 38980630
Purpose Of Review: Maturity-onset diabetes of the young (MODY) are monogenic forms of diabetes resulting from genetic defects, usually transmitted in an autosomal dominant fashion, leading to β-cell dysfunction. Due...
4.
Ciardullo S, Morieri M, Daniele G, Fiorentino T, Mezza T, Trico D, et al.
Acta Diabetol
. 2024 Jun;
61(8):941-950.
PMID: 38831203
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially...
5.
Ciardullo S, Mantovani A, Morieri M, Muraca E, Invernizzi P, Perseghin G
Liver Int
. 2024 Apr;
44(8):1762-1767.
PMID: 38597738
A recent Delphi consensus proposed a new definition for metabolic dysfunction associated steatotic liver disease (MASLD) and introduced a disease entity called MetALD, a condition in which steatotic liver disease...
6.
Trico D, Fadini G, Morieri M, Candido R, Disoteo O, Frontoni S, et al.
Diabetes Metab Res Rev
. 2024 Feb;
40(3):e3782.
PMID: 38402454
Aims: Glomerular hyperfiltration characterises the earliest stage of diabetic nephropathy and predicts adverse kidney and cardiovascular outcomes. We aimed to assess the prevalence and risk factors of glomerular hyperfiltration in...
7.
Fadini G, Longato E, Morieri M, Del Prato S, Avogaro A, Solini A
Lancet Reg Health Eur
. 2024 Feb;
38:100847.
PMID: 38328413
Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney...
8.
Ahmad A, Lim L, Morieri M, Tam C, Cheng F, Chikowore T, et al.
Commun Med (Lond)
. 2024 Jan;
4(1):11.
PMID: 38253823
Background: Precision medicine has the potential to improve cardiovascular disease (CVD) risk prediction in individuals with Type 2 diabetes (T2D). Methods: We conducted a systematic review and meta-analysis of longitudinal...
9.
Morieri M, Zhou H
Adv Biol (Weinh)
. 2023 Dec;
7(12):e2300464.
PMID: 38115206
No abstract available.
10.
Mantovani A, Morieri M, Aldigeri R, Palmisano L, Masulli M, Bonomo K, et al.
Diabetes Metab
. 2023 Nov;
50(1):101497.
PMID: 37992857
Aim: We examined whether metabolic dysfunction-associated steatotic liver disease (MASLD) with or without significant fibrosis (assessed by validated non-invasive biomarkers) was associated with an increased risk of prevalent chronic kidney...